Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 76, Issue 8, 2017, Pages 1374-1380

  Man, Ada ^a   Correa, Jeannette K ^b   Ziemek, Jessica ^c   Simms, Robert W ^c   Felson, David T ^c,d   Lafyatis, Robert ^e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b BOSTON UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NIHR Manchester Musculoskeletal Biomedical Research Unit   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Outcomes research; Patient perspective; Qualitative research; Systemic Sclerosis

Indexed keywords

ADULT; ARTICLE; CONSTRUCT VALIDITY; DIFFUSE SCLERODERMA; DISEASE DURATION; DISEASE SEVERITY; EXPLORATORY FACTOR ANALYSIS; FEMALE; HUMAN; INTERNAL CONSISTENCY; LIMITED SCLERODERMA; MAJOR CLINICAL STUDY; MALE; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; SYSTEMIC SCLEROSIS; TEST RETEST RELIABILITY; AGED; COMPLICATION; FACTOR ANALYSIS; INFORMATION PROCESSING; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOMETRY; QUALITATIVE RESEARCH; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; VALIDATION STUDY;

ADULT; AGED; FACTOR ANALYSIS, STATISTICAL; FEMALE; FOCUS GROUPS; HUMANS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PSYCHOMETRICS; QUALITATIVE RESEARCH; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; SURVEYS AND QUESTIONNAIRES;

EID: 85024396720     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210534     Document Type: Article

References (33)

1. Hudson M, Thombs BD, Steele R, et al. Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009;61:1112-20.
2. van Lankveld WGJM, Vonk MC, Teunissen H, et al. Appearance self-esteem in systemic sclerosis-subjective experience of skin deformity and its relationship with physician-assessed skin involvement, disease status and psychological variables. Rheumatol Oxf Engl 2007;46:872-6.
3. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
4. Malcarne VL, Hansdottir I, McKinney A, et al. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol 2007;34:359-67.
5. Richards HL, Herrick AL, Griffin K, et al. Systemic sclerosis: patients' perceptions of their condition. Arthritis Rheum 2003;49:689-96.
6. Pellar RE, Tingey TM, Pope JE. Patient-reported outcome measures in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 2016;42:301-16.
7. Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009;61:1257-63.
8. Mouthon L, Rannou F, Bérezné A, et al. Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Ann Rheum Dis 2007;66:1651-5.
9. Kallen MA, Mayes MD, Kriseman YL, et al. The symptom burden index: development and initial findings from use with patients with systemic sclerosis. J Rheumatol 2010;37:1692-8.
10. Silman A, Akesson A, Newman J, et al. Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998;25:79-83.
11. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
12. Frech TM, Khanna D, Maranian P, et al. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/distention. Clin Exp Rheumatol 2011;29:S22-25.
13. Raja J, Nihtyanova SI, Ong VH, et al. 287. An observational study of intravenous immunoglobulin therapy in the treatment of gastrointestinal involvement in systemic sclerosis. Rheumatology 2015;54:i161.
14. Volkmann ER, Furst DE. Management of systemic sclerosis-related skin disease: a review of existing and experimental therapeutic approaches. Rheum Dis Clin North Am 2015;41:399-417.
15. Strauss A, Corbin JM. Grounded theory in practice. Thousand Oaks, CA: SAGE, 1997.
16. NVivo qualitative data analysis Software. QSR Internationl Pty Ltd., 2012.
17. US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). UCM193282.pdf. Guid. Ind. Patient-Rep. Outcome Meas. Use Med. Prod. Dev. Support Labeling Claims. 2009. http://www.fda.gov/downloads/Drugs//Guidances/ UCM193282.pdf (accessed 6 Aug 2012).
18. Chren MM, Lasek RJ, Flocke SA, et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997;133:1433-40.
19. Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996;107:707-13.
20. Chren MM, Lasek RJ, Sahay AP, et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001;5:105-10.
21. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
22. Duruöz MT, Poiraudeau S, Fermanian J, et al. Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. J Rheumatol 1996;23:1167-72.
23. Muthén LK, Muthén BO. Mplus user's guide. 7th edn. Los Angeles, CA: Muthén & Muthén, 1998.
24. Marsh HW, Morin AJS, Parker PD, et al. Exploratory structural equation modeling: an integration of the best features of exploratory and confirmatory factor analysis. Annu Rev Clin Psychol 2014;10:85-110.
25. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model Multidiscip J 1999;6:1-55.
26. Allison PD. Missing data techniques for structural equation modeling. J Abnorm Psychol 2003;112:545-57.
27. Almeida C, Almeida I, Vasconcelos C. Quality of life in systemic sclerosis. Autoimmun Rev 2015;14:1087-96.
28. Herrick A, Rooney B, Finn J, et al. Lack of relationship between functional ability and skin score in patients with systemic sclerosis. J Rheumatol 2001;28:292-5.
29. Both H, Essink-Bot ML, Busschbach J, et al. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 2007;127:2726-39.
30. Brower LM, Poole JL. Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). Arthritis Rheum 2004;51:805-9.
31. Johnson SR, Hawker GA, Davis AM. The health assessment questionnaire disability index and scleroderma health assessment questionnaire in scleroderma trials: an evaluation of their measurement properties. Arthritis Rheum 2005;53:256-62.
32. Khanna D, Furst DE, Clements PJ, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832-40.
33. Hinchcliff ME, Beaumont JL, Carns MA, et al. Longitudinal evaluation of PROMIS-29 and FACIT-dyspnea short forms in systemic sclerosis. J Rheumatol 2015;42:64-72.